Product Information
ZOLMITRIPTAN 5 MG NASAL SPRAY is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $44.0393 per EA under NDC 45802071191. Its NADAC has been published 247 times since Jan 12, 2022.
FDA first approved this application on Sep 30, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the zolmitriptan market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
5 mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802071191
Classification
Generic
Dosage Form
SPRAY
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
ZOLMITRIPTANApproval Type
Generic (ANDA)
FDA Application
ANDA212469FDA Approved
9/30/2021
TE Code
AB
On Market Since
11/16/2021
Pharmacological Classes
Price Statistics
The NADAC for ZOLMITRIPTAN 5 MG NASAL SPRAY has been published 247 times since Jan 12, 2022, and over the history we have for it it has declined 43.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $44.0393 per EA |
|---|---|
| All-time high | $80.8103 (Nov 16, 2022) |
| All-time low | $38.6728 (Nov 19, 2025) |
| 52-week high | $45.0121 |
| 52-week low | $38.6728 |
| Median price | $60.6023 |
| Average price | $60.6199 |
| Largest weekly change | -33.7% (Apr 17, 2024) |
| Weeks tracked | 247 |
| Tracking since | Jan 12, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the zolmitriptan market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
zolmitriptan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZOLMITRIPTAN 5 MG NASAL SPRAY?
The current National Average Drug Acquisition Cost (NADAC) for ZOLMITRIPTAN 5 MG NASAL SPRAY, manufactured by Padagis Israel Pharmaceuticals Ltd, is $44.0393 per EA (NDC 45802071191), effective Sep 30, 2026.
How has the price of ZOLMITRIPTAN 5 MG NASAL SPRAY changed over time?
Over the history we have for it, the NADAC for ZOLMITRIPTAN 5 MG NASAL SPRAY has declined 43.0%. It has been tracked across 247 weekly CMS publications since Jan 12, 2022.
What are the highest and lowest recorded NADAC prices for ZOLMITRIPTAN 5 MG NASAL SPRAY?
Since Jan 12, 2022, the NADAC for ZOLMITRIPTAN 5 MG NASAL SPRAY has ranged from a low of $38.6728 (Nov 19, 2025) to a high of $80.8103 (Nov 16, 2022), with a median of $60.6023 per EA.
Are there cheaper alternatives to ZOLMITRIPTAN 5 MG NASAL SPRAY?
No other NADAC-published product currently shares the active ingredient and strength of ZOLMITRIPTAN 5 MG NASAL SPRAY in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZOLMITRIPTAN 5 MG NASAL SPRAY?
ZOLMITRIPTAN 5 MG NASAL SPRAY (NDC 45802071191) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.